- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
UK's Innovative Idea to Improve Adherence and Reduce Healthcare Waste
The UK government has come up with an innovative plan to increase public awareness of the increasing price of prescription drugs and what it costs the healthcare system
Patients in the United Kingdom pay a low flat rate equivalent to $12.80 for each of their prescription medications. Additionally, exemptions available for specific drug categories as well as for patient categories can result in negligence on the part of the patient to be attentive toward the cost of their own healthcare.
Now, the government has come up with an innovative plan to increase public awareness of the increasing price of prescription drugs and what it costs the healthcare system. The Department of Health in the United Kingdom plans to print the "indicative medicine costs" to the National Health Services on the label of all medications that cost more than the equivalent of $31, along with "funded by the UK taxpayer."
Read more at in-Pharma Technologist: http://bit.ly/1C310JO
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease
March 10th 2025Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimilar's FDA approval.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
